Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

Executive Summary

The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.

You may also be interested in...



J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

CEO Joaquin Duato told the J.P. Morgan Healthcare Conference that the drug maker hopes the $2bn acquisition can make one of its lead candidates, ARX517, the first PSMA-directed ADC for prostate cancer.

ESMO 2023: Tarlatamab Primed To Take Big BiTE Out Of SCLC Market

Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.

Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver

Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel